Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether NHS England plans to commission selective internal radiation therapy for patients with neuroendocrine tumours.

Radiotherapy treatment for cancer is highly individualised and decisions about cancer treatment are typically made by clinicians and multidisciplinary teams of healthcare professionals. They consider all aspects of a patient's health and circumstances when recommending treatment options. While certain treatments may not be advised for some patients, these decisions are based on medical assessments and what is best for the individual's overall health and well-being. For this reason, NHS England has not made an assessment on the potential impact of selective internal radiation therapy (SIRT) on survival outcome and quality of life for neuroendocrine tumour patients. However, the Department recognises the need to offer patients who need it the most suitable treatment, including SIRT.

NHS England commissions SIRT for chemotherapy refractory/intolerant metastatic colorectal cancer in adults in accordance with the criteria outlined at the following link:

https://www.england.nhs.uk/wp-content/uploads/2018/12/Selective-internal-radiation-therapy-for-chemotherapy-refractory-intolerant-metastatic-colorectal-cancer.pdf